TITLE

The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients

AUTHOR(S)
Grossman, Eric B.; Swan, Suzanne K.; Muirhead, Gary J.; Gaffney, Michael; Chung, Menger; Deriesthal, Herb; Chow, Diane; Raij, Leopoldo
PUB. DATE
July 2004
SOURCE
Kidney International;Jul2004, Vol. 66 Issue 1, p367
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients. Background. Erectile dysfunction (ED) is highly prevalent in men with renal disease. The clearance of sildenafil citrate, a highly effective oral treatment for ED, is decreased in men with severe renal insufficiency, but the pharmacokinetic and hemodynamic profiles during maintenance hemodialysis in men with end-stage renal disease have not been studied. Methods. Fifteen men undergoing chronic outpatient maintenance hemodialysis received a single 50-mg oral dose of sildenafil on 2 occasions, once 2 hours before, and once 2 hours after hemodialysis, with randomized assignment to sequence. Blood and dialysate samples were collected, and hemodynamic measurements were made. Results. Hemodialysis did not significantly clear either sildenafil or its primary metabolite, UK-103,320. Administration after hemodialysis was associated with a 17% higher peak plasma concentration and earlier time to peak, which were not clinically meaningful, whereas the overall extent of absorption and the elimination half-life were not affected. The average extent of drug bound to plasma protein was approximately 96% in hemodialysis patients. Intradialytic hypotension was not observed more frequently when sildenafil was administered before hemodialysis. Systolic blood pressure tended to decrease less during hemodialysis when subjects were treated with sildenafil before dialysis. Conclusion. The present study demonstrates that sildenafil is not cleared by hemodialysis, and the pharmacokinetic profile resembles more closely that observed in normal volunteers than that observed in patients with severe renal insufficiency. In addition, we found that sildenafil does not promote intradialytic hypotension.
ACCESSION #
13347220

 

Related Articles

  • Sildenafil citrate can improve erectile dysfunction among chronic hemodialysis patients. Ghafari, A.; Farshid, B.; Afshari, A. T.; Sepehrvand, N.; Rikhtegar, E.; Ghasemi, K.; Hatami, S. // Indian Journal of Nephrology;Jul-Sep2010, Vol. 20 Issue 3, p142 

    Erectile dysfunction (ED) is common among patients with end-stage renal disease (ESRD), who undergo hemodialysis (HD). The aim of this study was to evaluate the safety and effectiveness of sildenafil in male HD patients with ED. Twenty-seven HD patients were recruited for this prospective,...

  • Effects of sildenafil and vardenafil on erectile dysfunction and health-related quality of life in haemodialysis patients: a prospective randomized crossover study. Turk, Suleyman; Solak, Yalcin; Kan, Seyfullah; Atalay, Huseyin; Kilinc, Mehmet; Agca, Erhan; Bodur, Said // Nephrology Dialysis Transplantation;Nov2010, Vol. 25 Issue 11, p3729 

    Background. Erectile dysfunction (ED) is prevalent in end-stage renal disease (ESRD) and has been associated with impaired health-related quality of life (HRQoL). HRQoL, in turn, is related to morbidity and mortality in ESRD patients. Previous studies have shown improved HRQoL with ED treatment...

  • The Use of Oral Sildenafil Citrate In Hemodialysis Patients: A Multi- Center Double-Blind Placebo-Controlled Study. Sataa, Sallami; Dakhlia, Jamel; Oueslati, Baligh; Khemais, Klaa // Ibnosina Journal of Medicine & Biomedical Sciences;Mar2010, Vol. 2 Issue 2, p72 

    Efficacy and safety of oral sildenafil citrate use in hemodialysis patients is not very well documented. We undertook a study to evaluate the efficacy and safety of oral sildenafil in treating erectile dysfunction in hemodialysis patients. A total of 50 male hemodialysis patients (mean age 49.2...

  • Safety, efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer. Tomiyama, Nariaki; Hidaka, Muneaki; Hidaka, Hideo; Kawano, Yukihiro; Hanada, Norihisa; Kawaguchi, Hideki; Arimori, Kazuhiko; Nakamura, Chizuko // Cancer Chemotherapy & Pharmacology;Mar2010, Vol. 65 Issue 4, p807 

    The safety and efficacy of S-1 in hemodialysis patients have not been established. We evaluated the safety and efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer. A 66-year-old Japanese man with chronic renal failure, who had undergone hemodialysis three...

  • 384. Sildenafil works for erectile dysfunction in dialysis patients. Seibel, I.; de Figueiredo, C.E. Poll; Teloken, C. // Kidney;May/Jun2003, Vol. 12 Issue 3, p141 

    Objective: To evaluate the efficacy and safety of oral sildenafil to treat erectile dysfunction (ED) in chronic renal failure in patients on hemodialysis (HD). Methodology: A double-blind, randomized, placebo-controlled study of oral sildenafil (50 mg) administered as required in HD patients...

  • HRQOL on the upswing following sildenafil, vardenafil in ED.  // PharmacoEconomics & Outcomes News;7/24/2010, Issue 608, p12 

    The article discusses research on the effect of sildenafil and vardenafil on the erectile dysfunction and health-related quality of life in haemodialysis patients, referencing a study by S. Turk and colleagues published in the May 2, 2010 issue of "Nephrology Dialysis Transplantation."

  • Demographic trends in the Okinawa Dialysis Study (OKIDS) registry (1971–2000). Iseki, Kunitoshi; Tozawa, Masahiko; Iseki, Chiho; Takishita, Shuichi; Ogawa, Yoshihide // Kidney International;Feb2002, Vol. 61 Issue 2, p668 

    Demographic trends in the Okinawa Dialysis Study (OKIDS) registry (1971–2000).. Background: The clinical demographics of chronic dialysis patients are changing worldwide. However, long-term data from regional dialysis registries have not yet been analyzed and reported. Methods: The...

  • Survival advantage in Asian American end-stage renal disease patients1. Wong, Joyce S.; Port, Friedrich K.; Hulbert-Shearon, Tempie E.; Carroll, Caitlin E.; Wolfe, Robert A.; Agodoa, Lawrence Y.C.; Daugirdas, John T. // Kidney International;Jun1999, Vol. 55 Issue 6, p2515 

    Survival advantage in Asian American end-stage renal disease patients. Background. An earlier study documented a lower mortality risk for end-stage renal disease (ESRD) patients in Japan compared with the United States. We compared the mortality of Caucasian (white) and Asian American dialysis...

  • CKD pathophysiology and complications.  // Nephrology Dialysis Transplantation;May2013 Supplement, Vol. 28 Issue suppl_1, pi40 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics